The 3-Hydroxy-3-Methylglutaryl-CoA Reductase Inhibitor Lovastatin Reduces Severity of l-DOPA-Induced Abnormal Involuntary Movements in Experimental Parkinson's Disease
Stefan Schuster(Jena University Hospital), Erwan Bézard(Centre National de la Recherche Scientifique)
Cited by 87
Related Papers
Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy
|Movement Disorders|2017|846
Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations
|The Lancet Neurology|2015|508
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease
|Progress in Neurobiology|2015|472
Priorities in Parkinson's disease research
|Nature Reviews Drug Discovery|2011|430
Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function
|Nature Medicine|2003|381